Organic Active Ingredients TRIZ Cases

A quinazoline carboxamide azetidine combination targets PI3K/Akt/mTOR signaling to re-sensitize endocrine-resistant ER+ tumors.

Polymer adjuvants bind unpaired cysteines on tumor cells to localize TLR or STING agonists, reducing systemic inflammation.

A serotonin 3 receptor agonist composition raises cancer pain threshold with morphine-like analgesia while avoiding sedation and opioid-related side effects.

Structural modification of capsaicin yields stable, low-toxicity anti-tumor compounds with broad-spectrum activity across multiple cancer types.

Patient-specific S1P dosing reduces heart rate and conduction adverse events while preserving treatment effect in autoimmune disease.

Structural tuning of thieno- and thiazolo-pyrimidinones improves NOX4 potency, metabolic stability, and isoform selectivity.

A cyclopentylpyrazolamine derivative is tuned to selectively inhibit CDK2/Cyclin A, stalling the S phase and triggering tumor-cell apoptosis.

Citric acid, ethanol, and HFA134a stabilize pressurized tiotropium aerosol delivery while maintaining high fine particle fraction and bioequivalence.

Combining intestinal organoids with a TNFα inhibitor improves IBD symptom relief and helps inhibit intestinal mucosal fibrosis.

Position-specific seed-region modifications in siRNA reduce off-target toxicity while preserving on-target silencing activity.

Modified oligonucleotides lower SNCA mRNA and alpha-synuclein levels to reduce aggregation and neurodegeneration in related diseases.

A five-day siponimod titration before daily immediate-release maintenance reduces bradycardia and AV block risk in autoimmune treatment.

A Paenibacillus-derived exopolysaccharide forms an adhesive gel plug for rapid hemostasis in irregular or diffuse bleeding without long compression.

Antarctic brown algae β-1,3/1,6-glucan improves PD-1 antitumor response while helping reverse thrombocytopenia and leukocytopenia.

Selective EP4 agonist morpholine carboxamides treat GI and pulmonary disease while limiting systemic distribution and cardiovascular side effects.

Flat 300 mg BID delafloxacin avoids unreliable weight-based dosing in obese patients while reducing toxicity and monitoring burden.

COT inhibition offers a pharmacological route for NASH by reducing liver fibrosis and inflammation, with potential ACC inhibitor combination.

Polyalkylene oxide particle sizing controls osmotic pump dissolution start time without changing drug composition or adding coating steps.

Aromatic-cationic peptides target biotin to mitochondria, improving ATP-related cellular function without the high doses that disrupt cells.

Intramolecular tricyclic benzotriazole derivatives inhibit Keap1, activate Nrf2, and broaden treatment potential for oxidative stress diseases.

Selinexor co-crystals with succinic acid or vanillin improve solubility and stability through controlled crystallization into anhydrous forms.

In vivo encoded synthetic antibodies target Pseudomonas antigens to reduce biofilms and cut repeated dosing and purified antibody cost.

Aminopyrazole CHK1/2 inhibitors boost DNA damage and apoptosis in neuroblastoma and soft tissue sarcoma while limiting CDK1 off-target effects.

Chemotherapy agents activate therapeutic cells or conditioned media to improve tissue repair while avoiding genetic modification and growth factor toxicity.

Propylene glycol or polyethylene glycol keeps melflufen stable, avoids hazardous solvents, and limits degradation during storage.

A potent JAK1/JAK2 inhibitor compound improves treatment of inflammatory and cartilage-related disease while reducing dose and dosing frequency.

Ion-exchanged albumin removes transfection-inhibiting serum components, helping synthetic RNA enter cells with lower toxicity and mutation risk.

By inhibiting myosin-actin crossbridge formation, these quinazolinone dione compounds relieve HCM obstruction and reduce surgical burden.

By binding the TNF-alpha homodimer cavity, TIM-series molecules block homotrimer formation to deliver oral anti-inflammatory activity with lower toxicity.

Small-molecule remdesivir-related compounds offer a treatment route for pulmonary coronavirus infections when masks, distancing, or vaccines are insufficient.

Targeting ME1 addresses metabolic reprogramming in pulmonary hypertension, reducing vascular remodeling, RVSP, and right ventricular hypertrophy.

A high-concentration pregabalin liquid uses pH control for stability, palatability, and rapid relief of feline travel and vet-visit anxiety.

Antisense oligomers alter CNOT3 pre-mRNA splicing to raise PRPF31 levels and help prevent retinal degeneration in retinitis pigmentosa.

A combined miRNA, antithrombin, and electrolyte formulation uses nanoparticle delivery to target fibrosis, arrhythmia, and coagulopathy in cardiac arrest.

KCC2-targeting fused amino pyrimidines aim to improve variable psychosis outcomes by enhancing Cl− transport and restoring GABAergic function.

An ionic neutral lipid reduces phosphatidylcholine bilayer stabilization, enabling endosomal phase transition and better cellular uptake.

A flowable hydrophobically modified chitosan forms a stable tissue barrier that resists blood and exudate while degrading over about two weeks.

A triazole-linked GalNAc conjugate improves liver-targeted oligonucleotide delivery by enabling modular click-chemistry construction and ASGPR binding.

MTA-dependent PRMT5 inhibition targets MTAP-silenced tumors more selectively, improving anti-proliferative activity while limiting off-target toxicity.

ABCG2 inhibition shifts PPIX retention and distribution to improve porphyria therapy, fluorescence imaging, and photodynamic response.

Bicyclic urea compounds target the JAK2 V617F mutant through selective inhibition, helping preserve essential wild-type JAK2 functions.

Formula (I) TNF-alpha inhibitors use targeted structural variation to improve efficacy in inflammatory and autoimmune disease treatment.

Sprinkle capsules and liquid Ibrutinib suspensions improve oral delivery for B-cell cancers in patients with swallowing difficulties.

Lipophilic nucleotide modification enables carrier-free siRNA delivery to extrahepatic tissues while preserving in vivo stability and gene knockdown.

Repeated ultrasound pulses at multiple tissue sites improve nucleic acid delivery and gene expression while limiting cell damage and inflammation.

Selective 5-HT2C agonist dosing reduces seizure frequency and severity while avoiding the cardiac risks linked to less selective 5-HT2 drugs.

A dual solubilized-and-suspended API film boosts oral loading and bioavailability while preserving flexibility and easy administration.

miR-145 suppresses XPC, XPA, and RPA3 to lower NER in chemoresistant breast cancer and restore chemotherapy sensitivity.

Truncated midkine proteins delivered by lipid nanoparticles inhibit midkine activity, cell migration, and cancer cell survival.

An in situ PEG-peptide matrix conforms to irregular wounds, avoids photoinitiators, and degrades into healing-friendly byproducts.

Modified siRNA conjugates with phosphorothioate linkages improve LPA mRNA silencing stability for treating elevated Lp(a)-related disease.

A camptothecin derivative binds DDX5 and E3 ligase to degrade DDX5, inhibit topoisomerase I, and counter ABCG2-linked drug resistance.

Dual FLT3/IRAK4 inhibitor crystal and salt forms improve stability, weak hygroscopicity, and resistance-focused AML treatment.

Repurposing nicardipine targets lung cancer cell proliferation, offering a lower-cost treatment path with known safety data and reduced development time.

Periodic lymphocyte checks and patient symptom reporting help maintain fumarate treatment efficacy while reducing PML risk in multiple sclerosis.

Modified bexarotene derivatives address treatment-resistant cancers while also improving peripheral blood counts and immune system function.

Covalent organoarsenicals inhibit glutaminase in TNBC cells, improving selectivity and efficacy while reducing toxicity and resistance.

A 5-methyl-2-(1-piperazinyl)benzenesulfonic acid composition suppresses hyperkeratosis, dyskeratosis, and acantholysis to ease itching, pain, and skin thickening.

BMP and hemi-BMP measurements help identify wild-type LRRK2 Parkinson's patients likely to benefit from LRRK2 inhibitors while avoiding harm.

Localized PLGA nanoparticles in a thermoresponsive hydrogel deliver bindarit to the vessel adventitia to curb MCP-1-driven restenosis.

Targeted ligand-PROTAC conjugates improve membrane delivery, tissue selectivity, and protein degradation against resistant or hard-to-drug targets.

Nitroxyl radicals and short ester linkers improve polyphenol bioavailability, enabling stronger antioxidant antiaging action at lower concentrations.

Selective Cbl-b inhibition boosts T cell anti-tumor activity while preserving immune tolerance to help treat hematologic and solid cancers.

A controlled oral minoxidil release profile maintains therapeutic serum levels longer, reducing frequent dosing and adverse effects in hair loss treatment.

Intranasal NAC reaches the brain through olfactory and trigeminal pathways, bypassing the blood-brain barrier to treat brain injury.

A YEL002 composition addresses broad treatment limits by enhancing DNA repair and reducing inflammation across multiple disease conditions.

Modified polyoxyalkylene lipid conjugates reduce anti-PEO antibody formation while improving storage stability in stealth lipid nanoparticles.

Functionally selective pyrazolylmethanamine derivatives favor G-protein μ-opioid signaling to relieve pain while reducing tolerance and respiratory depression.

Xanthone-based oral compositions inhibit NIK and BAFF signaling to reduce allergic symptoms and antibody production with less patient burden.

A lecithin-based alphaxalone fat emulsion replaces Cremophor EL to improve solubility, control droplet size, and reduce hypersensitivity.

A cyclodextrin-based nimodipine injection cuts ethanol and solvent load while maintaining dilution stability and direct IV infusion compatibility.

Novel chemotypes activate parasitic flatworm TRP channels to induce paralysis and growth inhibition while addressing praziquantel resistance.

Selective ULK1/2 kinase inhibitors block autophagy in cancer and neuronal cells while avoiding retinopathy and off-target toxicity.

A semi-solid microsphere formulation localizes in the suprachoroidal space to sustain retinal drug delivery while minimizing intraocular pressure rise.

Targeted SNP probes identify genetic susceptibility to severe periodontitis, enabling earlier personalized treatment for related conditions.

Synthetic lysine analogs compete with amino acids needed for viral replication, reducing outbreak severity, duration, and recurrence.

Biodegradable groups in cationic lipids protect nucleic acids during delivery, then hydrolyze for faster clearance and lower toxicity.

rAAV delivery of APOE2 to the central nervous system counters APOE4-related Alzheimer's risk while reducing tau pathology and amyloid burden.

DLL3-targeted exatecan antibody-drug conjugates address SCLC relapse and resistance by selectively killing tumor cells while sparing normal cells.

A pH-controlled oral clonidine liquid stays stable at room temperature for months, reducing compounding errors and dosing risk.

A glucosylated hesperidin-rutin blend improves endothelial function and vascular flexibility where conventional vitamin P compounds fall short.

Capsid inhibition blocks HIV replication to support pre- and post-exposure prevention and reduce detectable virus in blood.

Pre-wetting nicotine powder with a sprayed binder in a fluid bed helps produce agglomerates with consistent size, nicotine content, and moisture.

Biodegradable polymer microspheres extend esketamine release to reduce repeat clinic visits and diversion risk while maintaining efficacy.

Detecting both negative and positive synovial pressure helps confirm intra-articular needle placement and identify joint effusion before injection.

Liver-targeted INHBE siRNA uses nucleotide modification and galactose conjugation to improve metabolic treatment while limiting off-target effects.

mTOR inhibitors help treat Fuchs' endothelial corneal dystrophy by limiting endothelial cell death and extracellular matrix overproduction.

A sealed inert-gas chamber decarboxylates cannabis while condensing vapors to preserve terpenes and cannabinoids and limit oxidation.

Chemotherapy-resistant stem cells enable non-myeloablative bone marrow reconstitution while reducing infection risk and recovery time.

A fusion protein mediates auxin-degron targeting of endogenous proteins in non-plant eukaryotic cells without genome editing.

A hyaluronic acid and polyol leave-on gel extends gum contact time to improve barrier protection, wound healing, and mouth feel.

A buffered naloxone nasal formulation uses glycerin and preservative-free sterilization to keep dosing stable for rapid overdose reversal.

A selective MC4R agonist compound addresses obesity treatment side effects while supporting weight loss and metabolic benefits without hERG inhibition.

A fluoropolymer-coated canister and separated dose counter keep fluticasone particles stable and doses consistent in HFA inhalers.

Modified dsRNAi compositions selectively silence MAPT expression to lower Tau protein levels and address tauopathy progression.

A sesame oil and solvent-based oral native testosterone composition improves gut absorption and bioavailability while avoiding side effects of modified derivatives.

Selective HDAC6 degraders link an HDAC6 inhibitor to an E3 ligase ligand to cut toxicity and suppress neoplastic cell growth.

Targeting PRAP1 with a modified polypeptide or RNA inhibitor lowers triglycerides and phospholipids while avoiding the side effects of standard drugs.

Standardized Stachytarpheta extracts replace rare source plants to enable feasible vitiligo treatment with repigmentation and no reported toxicity.

A two-part dried protein and reconstitution format extends stem cell cosmetic shelf-life at room temperature while preserving wrinkle-reducing activity.

These compounds target c-Abl’s myristate pocket and cross the blood-brain barrier to address ineffective Alzheimer’s treatments.

See how a liposome formulation encapsulates rapamycin to address low solubility, improve bioavailability, and remain stable after lyophilization.

Varying benzoyl aniline substituents broadens antibacterial coverage, while BAB159 with polymyxin E boosts activity against resistant strains.

High-risk neuroblastoma resists aggressive therapy; AOH1160 targets PCNA to disrupt DNA repair, induce apoptosis, and sensitize cells to cisplatin.

Branched poly(β-amino ester) vectors address limited transfection and toxicity through tailored polymer architecture and biocompatible components.

Selective TRPV1 antagonism targets chronic ocular surface pain while avoiding anesthesia associated with some pain therapies.

These derivatives inhibit neuronal nicotinic acetylcholine receptors to address medically refractory and nerve agent-induced seizures.

High sugar-alcohol levels can worsen gliptin aftertaste and stability; artificial non-sugar alcohol sweeteners help balance both in liquid formulations.

Systematic ASK1 inhibitor compounds target NASH and dysfunctional tissue healing while addressing potency, selectivity, and synthesis complexity.

LPAR1 antagonist compounds vary fatty-acid chains and molecular structure to address gaps in selectivity, potency, and metabolic stability.

An amine and carbonic acid adduct combine antiviral and antimycotic activity to address influenza-Aspergillus superinfections with one active ingredient.

Novel benzodiazolium compounds aim to prolong airway ENaC inhibition and reduce renal exposure, helping enhance mucociliary clearance without hyperkalaemia.

An analyte signature identifies obesity phenotypes so dietary, exercise, and pharmacological plans can be tailored to improve response consistency.

CD98hc-targeted LNPs bind BBB transporters to carry nucleic acid cargo into the CNS through intravenous dosing.

PTPN2 inhibition strengthens lymphoid-cell signaling to address immunosuppressive tumors and CAR-T toxicities in cancer treatment.

Combining aripiprazole with a MEK inhibitor targets resistance by stabilizing BIM, increasing BH3-only proteins, and promoting PARP cleavage.

Psilocybin and psychological support address inadequate treatments by targeting neural plasticity, cognitive function, and inflammation.

Carbonyl-reactive aminooxy monomers form hydrazone linkages for efficient attachment of diverse ligands to oligonucleotides.

A small-molecule splicing modulator binds ATXN3 pre-mRNA to reduce full-length ATXN3 and address SCA3 disease progression.

A two-phase melatonin release balances faster sleep onset with sustained sleep duration in a multi-ingredient composition.

NaDES extracts and stabilizes olive oil polyphenols in a single step, avoiding toxic solvents while supporting anti-inflammatory skin treatments.

A platelet-rich biological scaffold addresses mesh complications by combining mechanical support with native tissue repair in POP surgery.

Current therapies lack effective KIF18A inhibitors; small-molecule compounds block its ATPase activity to arrest mitosis and induce cancer-cell apoptosis.

Heterocyclic compounds activate TREM2 to address neuroimmune aspects of neurodegenerative disease beyond amyloid and Tau targeting.

Existing treatments lack effective BAF modulation; pyrazine derivatives target BRG1 and BRM to alter chromatin remodeling in cancer-related disorders.

Selective lymphocyte depletion with cladribine addresses inadequate myasthenia gravis symptom control while limiting severe side effects.

Fatty-acid substituted pyrrolopyrimidines inhibit CDK4/6, blocking cell-cycle progression in cancer cells and CSCs.

Polyvalent-ion crosslinking forms a local gel that limits contrast-agent diffusion, sharpens lesion labeling, and prolongs drug release.

Ion-exchange chromatography separates caffeoylquinic acids from botanical extracts to improve purity, control ratios, and reduce off-tastes.

An orosoluble SAMe–probiotic formulation addresses instability, poor bioavailability, taste, and adherence in mood-disorder treatment.

Polymorph variability affects solubility and storage stability; controlled crystallization selects form E for low hygroscopicity.

Combining lurbinectedin with PD-1, PD-L1, or CTLA-4 inhibitors induces immunogenic cell death and strengthens tumor control in solid tumors.

See how controlled crystallization isolates MDM2 inhibitors in high-purity forms while supporting scalable synthesis and p53 pathway restoration.

Systematic substituent changes in benzamide enaminones target drug-resistant epilepsy, with potential to reduce seizure frequency at lower doses and limit side effects.

Conventional topical treatments can drive resistance and recurrence; human-derived Janthinobacterium lividum helps restore skin microbiome balance.

See how NCOA7-activating compounds target vascular inflammation, including PAH, while SNP rs11154337 editing addresses genetic susceptibility.

Combining 5HT2A agonists with receptor modulators can limit hallucinogenic effects while treating depression, PTSD, anxiety, and substance use disorders.

Protecting-group sequences, catalysts, deprotecting agents, and methylene reagents streamline preparation of HIV integrase compounds.

Dry powder formulations place vismodegib or taladegib in deep lung tissue, targeting pulmonary fibrosis while limiting systemic adverse effects.

Poorly selective cardiac sarcomere agents can cause adverse effects; aficamten targets cardiac myosin while maintaining exercise capacity with beta blockers.

With no validated TNBC molecular target, anti-B7-H4 agents bind overexpressed B7-H4 to inhibit tumor growth and enhance immune response.

Trimming and drying Cannabis flowers before ethanol maceration and percolation avoids winterization while preserving THC and terpene ratios.

Bendamustine formulations using PEG, propylene glycol, chloride sources, or antioxidants limit hydrolysis and impurities during 15-month storage.

Acid- and bile-resistant strains paired with inulin, fiber, and apple pectin support survival and colon fermentation.

An aqueous C1-C4 alcohol process dissolves non-crystalline DFL, then cooling forms high-purity crystals for nutritional and pharmaceutical use.

Reversible BTK inhibition modulates B cell function without permanent depletion, supporting treatment research across inflammatory and cancer indications.

Oral DGLA before pollen dispersal reduces sneezing, nasal congestion, discharge, and itchy eyes in allergic rhinitis or conjunctivitis.

Sav1-targeting shRNA modulates Hippo signaling to support cardiomyocyte regeneration and heart-function recovery in DMD.

Novel solid forms of a catecholamine prodrug improve oral bioavailability and support sustained plasma exposure for Parkinson’s treatment.

Intratumoral oncolytic HSV followed by systemic checkpoint inhibition targets injected and uninjected tumors while addressing limited response and toxicity.

Ifetroban blocks thromboxane A2 receptors, reducing severity of aspirin-exacerbated respiratory disease symptoms and decreasing rescue medication requirements.

Anaplastic lymphoma kinase inhibitors suppress the STING-mediated type I interferon response, mitigating organ dysfunction and mortality associated with sepsis.

Tetrahydrobiopterin enhances nitric oxide synthase activity to stimulate salivary gland function and treat xerostomia.

A hydrophilic polymeric gel plug absorbs benzalkonium chloride from eye drop solutions, reducing ocular toxicity while maintaining bottle sterility.

A zileuton cream formulation minimizes systemic absorption while maintaining physiochemical stability.

A dual-chamber kit reconstitutes imatinib powder with diluent just before administration.

Administering a specific compound blocks tau hyperphosphorylation, reducing neurodegenerative symptoms from repeated concussions.

Bioadhesive triamcinolone acetonide formulations maintain drug concentration using inert atmosphere processing and lidocaine hydrochloride substitution.

A polymer microparticle preparation process uses benzyl alcohol to enable spontaneous particle formation through organic solvent diffusion.

Reversible disulfide bonds enable dynamic exchange with glutathione to overcome rapid clinical acquired resistance in KRAS mutant-driven cancers.

Oligonucleotide probes detect HLA-B alleles in patient samples to identify genetic markers associated with severe cutaneous adverse drug reactions.

Pyrimido[5,4-d]pyrimidine compounds inhibit signal enzymes to control cell proliferation in cancer treatment.

Substituent modifications at R positions optimize solubility and half-life while maintaining DGAT2 inhibiting activity.

Marine-derived quinolinone derivatives treat HSV-1 infections while bypassing drug resistance mechanisms found in conventional nucleoside antivirals.

Captodiamine increases hypothalamic BDNF expression via sigma-1 agonism and 5-HT2C antagonism to address hyperphagia and obesity.

Rotary tablet presses manufacture soft chew tablets with low hardness and friability, resolving complexity issues in conventional molding processes.

Assays targeting the ActRII pathway identify agents that prevent cell detachment, addressing ineffective metastatic cancer treatments.

A monodose topical veterinary composition combines imidacloprid, moxidectin, and praziquantel with an aprotic solvent to treat canine parasitic infestations.

A nucleic acid complex links a single-stranded sequence to a cross-linked double-stranded structure via covalent bonds.

Combining JNK inhibition with TRAIL administration targets pancreatic cancer stem cells through selective apoptosis induction.

C-glycoside compounds modulate immune responses to prevent cutaneous disorders exacerbated by environmental stresses and UV radiation.

Small organic ligands stabilize the folding intermediate of cellular prion protein to promote lysosomal degradation and inhibit pathogenic maturation.

Chemical modification of heparin reduces anticoagulant activity while maintaining strong heparanase inhibition.

Thiazole derivative adenosine A2A receptor antagonist suppresses wearing-off and dyskinesias during L-DOPA therapy.

Specific Nerium fractions provide neuroprotection, slowing disease progression in Huntington's and Alzheimer's patients.

Heterocyclic GLP-1 agonists stimulate insulin secretion and suppress glucagon release to manage blood glucose levels.

Tricyclic compounds target bromodomain proteins to treat cancers lacking effective therapies.